Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies-Reference-Cited by-同舟云学术

Optimisation of dose level and vaccination schedule for the VLA15 Lyme borreliosis vaccine candidate among healthy adults: two randomised, observer-blind, placebo-controlled, multicentre, phase 2 studies

Published:2024-09 Issue:9 Volume:24 Page:1045-1058
ISSN:1473-3099
Container-title:The Lancet Infectious Diseases
language:en
Short-container-title:The Lancet Infectious Diseases

Author:

Bézay Nicole,Wagner Laura,Kadlecek Vera,Obersriebnig Michaela,Wressnigg Nina,Hochreiter Romana,Schneider Martina,Dubischar Katrin,Derhaschnig Ulla,Klingler Anton,Larcher-Senn Julian,Eder-Lingelbach Susanne,Bender Wolfgang

Publisher

Elsevier BV

Reference33 articles.

1. Lyme borreliosis—from tick bite to diagnosis and treatment;Stanek;FEMS Microbiol Rev,2018

2. Changing trends in age and sex distributions of Lyme disease—United States, 1992–2016;Kugeler;Public Health Rep,2022

3. Estimating the frequency of Lyme disease diagnoses, United States, 2010–2018;Kugeler;Emerg Infect Dis,2021

4. Incidence of Lyme borreliosis in Europe from national surveillance systems (2005–2020);Burn;Vector Borne Zoonotic Dis,2023

5. Incidence of Lyme borreliosis in Europe: a systematic review (2005–2020);Burn;Vector Borne Zoonotic Dis,2023

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel recombinant vaccinia virus-vectored vaccine affords complete protection against homologous Borrelia burgdorferi infection in mice;Emerging Microbes & Infections;2024-09-02

2. Vaccination hesistancy in Lyme borreliosis;The Lancet Infectious Diseases;2024-09

3. Boosting immunity to protect from tickborne Lyme disease;The Lancet Infectious Diseases;2024-07

4. Immunogenicity and safety of an 18-month booster dose of the VLA15 Lyme borreliosis vaccine candidate after primary immunisation in healthy adults in the USA: results of the booster phase of a randomised, controlled, phase 2 trial;The Lancet Infectious Diseases;2024-07